Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study.

ABSTRACT:

Background

Janus kinase inhibitors (JAKi) are new targeted synthetic disease-modifying antirheumatic drugs (DMARDs) licenced in the UK to treat rheumatoid and psoriatic arthritides. Unlike currently often prescribed biological DMARDs, they target a different part of the inflammatory pathway and are taken orally. The aim of this study was to explore what UK-based rheumatology clinicians and inflammatory arthritis (IA) patients think about the awareness, prescription and use of JAKi; how they compare with biologics; and how the COVID-19 pandemic has affected how JAKi are viewed and prescribed.

Methods

Rheumatology clinicians and IA patients completed online surveys and participated in interviews/focus groups between September 2021 and January 2022. Survey data were analysed de

SUBMITTER: de Souza S 

PROVIDER: S-EPMC10792861 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature